SG11201707683YA - C/ebp alpha sarna compositions and methods of use - Google Patents
C/ebp alpha sarna compositions and methods of useInfo
- Publication number
- SG11201707683YA SG11201707683YA SG11201707683YA SG11201707683YA SG11201707683YA SG 11201707683Y A SG11201707683Y A SG 11201707683YA SG 11201707683Y A SG11201707683Y A SG 11201707683YA SG 11201707683Y A SG11201707683Y A SG 11201707683YA SG 11201707683Y A SG11201707683Y A SG 11201707683YA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- ebp alpha
- sarna compositions
- compositions
- alpha sarna
- Prior art date
Links
- 108091029810 SaRNA Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229940078677 sarna Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562150889P | 2015-04-22 | 2015-04-22 | |
US201562235778P | 2015-10-01 | 2015-10-01 | |
US201662308521P | 2016-03-15 | 2016-03-15 | |
PCT/GB2016/051117 WO2016170349A1 (en) | 2015-04-22 | 2016-04-21 | C/ebp alpha sarna compositions and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201707683YA true SG11201707683YA (en) | 2017-11-29 |
Family
ID=55948895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201707683YA SG11201707683YA (en) | 2015-04-22 | 2016-04-21 | C/ebp alpha sarna compositions and methods of use |
Country Status (9)
Country | Link |
---|---|
US (2) | US10912790B2 (en) |
EP (1) | EP3286316A1 (en) |
JP (4) | JP6768701B2 (en) |
KR (2) | KR102599712B1 (en) |
CN (2) | CN114525279A (en) |
AU (3) | AU2016251415B9 (en) |
CA (1) | CA2980975A1 (en) |
SG (1) | SG11201707683YA (en) |
WO (1) | WO2016170349A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3236835A1 (en) * | 2013-11-22 | 2015-05-28 | Mina Therapeutics Limited | C/ebp alpha short activating rna compositions and methods of use |
WO2018104538A1 (en) * | 2016-12-08 | 2018-06-14 | Curevac Ag | Rna for treatment or prophylaxis of a liver disease |
CA3075205A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | Stabilized hnf4a sarna compositions and methods of use |
US20200208152A1 (en) * | 2017-09-08 | 2020-07-02 | Mina Therapeutics Limited | Stabilized sarna compositions and methods of use |
CN108103108A (en) * | 2018-01-30 | 2018-06-01 | 上海交通大学医学院附属瑞金医院 | Preparation and application of Cebpa gene-deleted zebra fish mutant |
US20210024928A1 (en) * | 2018-02-16 | 2021-01-28 | Mina Therapeutics Limited | C/ebp alpha sarna compositions and methods of use |
EP3778892A4 (en) * | 2018-04-10 | 2022-01-19 | Ractigen Therapeutics | Novel small activating rna |
WO2019239144A1 (en) | 2018-06-15 | 2019-12-19 | Mina Therapeutics Limited | Combination therapies comprising c/ebp alpha sarna |
CN114585384A (en) * | 2019-07-26 | 2022-06-03 | 米纳治疗有限公司 | Compositions and methods using C/EBP alpha sarRNA |
EP4069848A4 (en) * | 2019-12-03 | 2024-02-28 | Merck Sharp & Dohme LLC | In vitro cell based potency assay |
GB202019692D0 (en) * | 2020-12-14 | 2021-01-27 | Apterna Ltd | Aptamer-sirna fusions |
EP4329777A1 (en) | 2021-04-28 | 2024-03-06 | MiNA Therapeutics Limited | Combination therapies comprising c/ebp alpha sarna |
KR102428121B1 (en) * | 2021-10-20 | 2022-08-08 | 주식회사 네오나 | Delivery system for preventing or treating of liver cancer comprising modified rt-let7 as an active ingredient |
CN114306367B (en) * | 2021-08-27 | 2023-03-28 | 赵小洋 | Composition containing C/EBP alpha-saRNA |
US20240207204A1 (en) * | 2022-12-12 | 2024-06-27 | Regeneron Pharmaceuticals, Inc. | Treatment Of Type 2 Diabetes With Hepatocyte Nuclear Factor 4 Alpha (HNF4A) Agonists |
WO2024134199A1 (en) * | 2022-12-22 | 2024-06-27 | Mina Therapeutics Limited | Chemically modified sarna compositions and methods of use |
WO2024165876A2 (en) * | 2023-02-10 | 2024-08-15 | Mina Therapeutics Limited | Compositions and methods of using c/ebp alpha sarna |
WO2024175887A1 (en) | 2023-02-22 | 2024-08-29 | Mina Therapeutics Limited | Compositions and methods of using c/ebp alpha sarna |
KR20240138691A (en) * | 2023-03-13 | 2024-09-20 | 부산대학교 산학협력단 | Biomarker composition for diagnosing rheumatoid arthritis, diagnostic kit using the same, and method for diagnosing rheumatoid arthritis using the same |
CN118480552B (en) * | 2024-01-18 | 2024-10-01 | 成都先衍生物技术有限公司 | SARNA for targeting CEBPA gene expression and application thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2990410A1 (en) * | 2004-08-10 | 2016-03-02 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
CA2743074A1 (en) * | 2008-11-13 | 2010-05-20 | Erasmus University Medical Center Rotterdam | Efficient detection of double mutants of the cebpa gene in aml. |
CN102612560B (en) * | 2009-06-16 | 2017-10-17 | 库尔纳公司 | By suppressing to treat the related diseases of PON1 for the natural antisense transcript of PON1 (PON1) |
GB201010557D0 (en) * | 2010-06-23 | 2010-08-11 | Mina Therapeutics Ltd | RNA molecules and uses thereof |
EP3702460A1 (en) * | 2010-11-12 | 2020-09-02 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
WO2012175958A1 (en) * | 2011-06-21 | 2012-12-27 | Mina Therapeutics Limited | Albumin production and cell proliferation |
DE102011079572A1 (en) * | 2011-07-21 | 2013-01-24 | Endress + Hauser Conducta Gesellschaft für Mess- und Regeltechnik mbH + Co. KG | Gradiometer for determining the electrical conductivity of a medium contained in a container |
WO2014071379A1 (en) * | 2012-11-05 | 2014-05-08 | Pronai Therapeutics, Inc. | Dosing and administration of oligonucleotide cancer therapies |
CN104884637A (en) * | 2012-11-05 | 2015-09-02 | 普隆奈治疗公司 | Methods of using biomarkers for the treatment of cancer by modulation of BCL2 expression |
EP2920325A2 (en) * | 2012-11-15 | 2015-09-23 | Bristol-Myers Squibb Company | Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent |
CA3236835A1 (en) | 2013-11-22 | 2015-05-28 | Mina Therapeutics Limited | C/ebp alpha short activating rna compositions and methods of use |
EP3316894A4 (en) * | 2015-07-02 | 2019-06-19 | City of Hope | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof |
-
2016
- 2016-04-21 US US15/568,139 patent/US10912790B2/en active Active
- 2016-04-21 KR KR1020177030397A patent/KR102599712B1/en active IP Right Grant
- 2016-04-21 KR KR1020237037891A patent/KR20230156961A/en active Application Filing
- 2016-04-21 EP EP16721209.1A patent/EP3286316A1/en active Pending
- 2016-04-21 CN CN202210140475.5A patent/CN114525279A/en active Pending
- 2016-04-21 AU AU2016251415A patent/AU2016251415B9/en active Active
- 2016-04-21 CN CN201680034224.1A patent/CN108291228A/en active Pending
- 2016-04-21 WO PCT/GB2016/051117 patent/WO2016170349A1/en active Application Filing
- 2016-04-21 SG SG11201707683YA patent/SG11201707683YA/en unknown
- 2016-04-21 CA CA2980975A patent/CA2980975A1/en active Pending
- 2016-04-21 JP JP2017554886A patent/JP6768701B2/en active Active
-
2019
- 2019-07-31 AU AU2019210578A patent/AU2019210578B2/en active Active
-
2020
- 2020-09-23 JP JP2020158141A patent/JP6931733B2/en active Active
- 2020-12-09 US US17/117,025 patent/US20210187007A1/en active Pending
-
2021
- 2021-08-16 JP JP2021132267A patent/JP2021192616A/en active Pending
-
2022
- 2022-04-08 AU AU2022202355A patent/AU2022202355A1/en active Pending
-
2024
- 2024-03-13 JP JP2024038710A patent/JP2024079713A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210187007A1 (en) | 2021-06-24 |
KR20230156961A (en) | 2023-11-15 |
JP2021192616A (en) | 2021-12-23 |
JP6768701B2 (en) | 2020-10-14 |
JP2018516545A (en) | 2018-06-28 |
JP2024079713A (en) | 2024-06-11 |
CN108291228A (en) | 2018-07-17 |
CN114525279A (en) | 2022-05-24 |
US20200376020A1 (en) | 2020-12-03 |
CA2980975A1 (en) | 2016-10-27 |
US10912790B2 (en) | 2021-02-09 |
AU2019210578B2 (en) | 2022-01-13 |
KR102599712B1 (en) | 2023-11-09 |
JP2021000119A (en) | 2021-01-07 |
AU2019210578A1 (en) | 2019-08-22 |
AU2022202355A1 (en) | 2022-04-28 |
EP3286316A1 (en) | 2018-02-28 |
AU2016251415B9 (en) | 2019-05-23 |
AU2016251415B2 (en) | 2019-05-02 |
JP6931733B2 (en) | 2021-09-08 |
WO2016170349A1 (en) | 2016-10-27 |
KR20170136542A (en) | 2017-12-11 |
AU2016251415A1 (en) | 2017-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201707683YA (en) | C/ebp alpha sarna compositions and methods of use | |
GB2582482B (en) | CASZ compositions and methods of use | |
HK1256608A1 (en) | Flavonoid compositions and methods of use | |
HK1247238B (en) | Engineered crispr-cas9 compositions and methods of use | |
ZA201707981B (en) | Compositions of obeticholic acid and methods of use | |
GB2582100B (en) | CAS12C Compositions and methods of use | |
ZA202104969B (en) | Compositions comprising 15-hepe and methods of using the same | |
HK1250657A1 (en) | High elasticity hyaluronan compositions and methods of use thereof | |
ZA201906169B (en) | Synthekine compositions and methods of use | |
HUE051713T2 (en) | Compositions of selenoorganic compounds and methods of use thereof | |
HK1243354B (en) | Novel iodophor composition and methods of use | |
HK1251979A1 (en) | Peptide compositions and methods of use | |
IL265761A (en) | Terlipressin compositions and their methods of use | |
HK1247136A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
HK1252057A1 (en) | Novel method of use and compositions | |
HK1250345A1 (en) | Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same | |
HK1231395A1 (en) | Bioactive heme-haloperoxidase compositions and methods of their use | |
EP3253396A4 (en) | Probiotic compositions and methods of use | |
HK1243404A1 (en) | Tryptamide compositions and methods of use | |
GB201511799D0 (en) | Composition and methods of treatment | |
HK1248527A1 (en) | Dental compositions and methods of use | |
IL261794A (en) | Compositions and methods of their use | |
IL247645A0 (en) | Compositions of selenoorganic compounds and methods of use thereof |